spacer
home > ebr > autumn 2003 > upping the anti - keeping ahead of antibiotic resistance
PUBLICATIONS
European Biopharmaceutical Review

Upping the Anti - Keeping Ahead of Antibiotic Resistance

The prevalence of antibacterial resistance seems to be rising, yet few new antibiotics have been approved in recent years. How dire is the situation and what is Enanta doing to address it?

Drug resistance is continually increasing and the supply of new antibiotics has slowed. Resistance to antibiotics varies by geographic region and there is no doubt that clinically important species of bacteria such as Streptococci, one of the major causes of respiratory tract infections, have developed resistance to more than one antibiotic. A recent study completed by the Centers for Disease Control in the US concluded that by next year 40 per cent of Streptococci will be resistant to both penicillins and macrolides.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Aimee Dingwell, News Editor at BioCentury Publications Inc, talks to Spiros Jamas, President and CEO of Enanta

Dr Spiros Jamas graduated from the University of Manchester Institute of Science and Technology, England, in 1981 with a BSc (Hons) in Chemical Engineering. He also holds a MSc in Food Science and Technology and a PhD in Biotechnology from the Massachusetts Institute of Technology.

In 1988, Dr Jamas founded and served as President, CEO and Director of Alpha-Beta Technology, a company that developed medical applications of carbohydrates. During his tenure at Alpha-Beta, he was instrumental in raising $200 million through venture capital, as well as public financings. Dr Jamas has also directed two INDs, five Phase I, three Phase II, and two Phase III clinical trials, while concurrently acquiring another privately held biotechnology company. Following this, he held the position of President and CEO of Repair Inc, a biopharmaceutical company that developed sustained-release angiogenesis therapies for the repair of diseased organs and tissues.

Dr Jamas has served as President and CEO of Enanta since the company's inception in 1999, providing scientific and business leadership.

spacer
Aimee Dingwell
spacer
spacer
spacer
Dr Spiros Jamas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioBLU® family grows

Juelich/Hannover, October 14th, 2013 – At this year’s BIOTECHNICA in Hannover, Germany Eppendorf has presented the newest members of its single-use bioreactor family BioBLU for the first time. With the new single-use bioreactor BioBLU 1c for cell culture and BioBLU 1f for microbial applications Eppendorf further extends its portfolio of rigid wall single-use bioreactors. These 1 L vessels are bridging the gap between the BioBLU 0.3 c/f mini single-use bioreactors and the larger vessels of the BioBLU family. Users in cell culture, who want to combine the advantages of single-use technology with the proven qualities of stirred-tank bioreactor design can now benefit from an unmatched portfolio of rigid wall stirred tank single-use bioreactors with working volumes from 100 mL – 40 L.
More info >>

White Papers

Autoinjectors From Planning to Launch

SHL Group

Looking at the rising trend towards self-administration therapies, injectable drug delivery devices such as pen injectors, autoinjectors and needle free injectors show a significant growth potential in the near future. In 2010, the pen systems and autoinjectors market was estimated to be worth over $0.58bn, a growth of 8-10% from previous years. It is estimated that the market will continue to grow steadily between 10-15% over the forecast period. It will reach $0.87bn in 2013 and $1.07bn in 2015. (Visiongain, June, 2011)
More info >>

 
Industry Events

Analytical Method Development, Validation and Transfer

9-10 September 2014, Maritim proArte Hotel, Berlin, Germany

Informa life Sciences Analytical Method Development, Transfer and Validation is a dedicated forum focusing solely on new method development, validation and transfer for pharmaceutical and generics manufacturers.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement